重酒石酸氢可酮(Hydrocodone bitartrate) - 药物靶点：Opioid receptors_在研适应症：疼痛_专利_临床

概要

基本信息

简介Hydrocodone bitartrate是一种阿片类止痛药，通常被称为“氢可酮”。其化学名为4,5(alpha)-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5) 或morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5 alpha)-, [R (R*, R*)]-2,3-dihydroxybutanedioate (1:1),hydrate (2:5)。氢可酮是美国用于急性和慢性疼痛的最常用药物，2012年的处方量超过1.35亿。由于其易获取性和滥用模式，氢可酮被认为是引起滥用和误用的阿片类药物的主要驱动力。其机制是通过刺激阿片受体发挥镇痛作用。

药物类型

小分子化药

别名

酒石酸氢可酮、AFI-001、ATLP-03

+ [9]

靶点

Opioid receptors

作用方式

激动剂

作用机制

Opioid receptors激动剂(阿片样受体激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症

疼痛

非在研适应症

慢性骨关节炎慢性疼痛终末期肾脏病+ [3]

原研机构-

在研机构

Purdue Pharma LP

非在研机构

Teva Branded Pharmaceutical Products R&D, Inc.

Societal CDMO Gainesville LLC

Zogenix, Inc.

+ [1]

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2013-10-25),

疼痛

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C22H29NO10

InChIKeyZICRJLQTAUVSDU-NSJZFRMTSA-N

CAS号34195-34-1

关联

38

项与重酒石酸氢可酮相关的临床试验

ChiCTR2500101383

/ Not yet recruitingN/AIIT

Dexmedetomidine Added to Ropivacaine for Transversus Abdominis Plane Block Improves postoperative quality of life after Radical Colorectal Cancer Surgery: A Randomized Double-Blind Trial

开始日期2025-04-30

申办/合作机构-

ChiCTR2500107474

/ Not yet recruiting临床4期IIT

Efficacy and safety study of low-dose oxycodone versus tramadol in patients with moderate cancer pain from different ethnic groups: a multicenter randomized controlled open-label trial

开始日期2025-04-17

申办/合作机构

四川省肿瘤医院（四川省第二人民医院四川省癌症防治中心）

[+1]

NCT06780202

/ Recruiting临床2期IIT

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

This clinical trial aims to determine the effects of a 6-day low-dose methylprednisolone course on pain, nausea, and total opioid consumption in patients undergoing foot and ankle surgeries.
The secondary objective of the study is to determine and monitor the effects of the course on complications following surgery and patient-reported outcomes

开始日期2025-01-27

申办/合作机构

Emory University

100 项与重酒石酸氢可酮相关的临床结果

登录后查看更多信息

100 项与重酒石酸氢可酮相关的转化医学

登录后查看更多信息

100 项与重酒石酸氢可酮相关的专利（医药）

登录后查看更多信息

1,589

项与重酒石酸氢可酮相关的文献（医药）

2025-12-01·HISTOCHEMISTRY AND CELL BIOLOGY

Bioactive and degradable collagen-based hydrogel encapsulated with microspheres containing basic fibroblast growth factor (bFGF) and interleukin (IL)-10 promotes recovery following traumatic spinal cord injury in rats

Article

作者: Hjazi, Ahmed

Traumatic spinal cord injury (TSCI) is a severe event within the central nervous system, leading to the impairment of sensory and motor abilities at the injury site in the spinal cord. Current therapeutic approaches offer limited efficacy in improving recovery, underscoring the need to explore alternative treatments. In the present study, we examined the sustained co-delivery of basic fibroblast growth factor (bFGF) and interleukin-10 (IL-10), encapsulated in microspheres and incorporated into a collagen-based hydrogel, for its effects on the healing of TSCI in an animal model. Seventy-five male Sprague Dawley rats were randomly divided into five groups: control, TSCI, hydrogel, microspheres, and hydrogel loaded with microspheres (Hyd + Micro). Tissue samples were collected from the injury site for further evaluation. Compared to the TSCI group, treatment groups demonstrated notably higher numerical densities of neurons and greater motor neuron health, as well as increased levels of vascular endothelial growth factor (VEGF) and antioxidative factors (catalase [CAT], glutathione [GSH], and superoxide dismutase [SOD]), and improved neurological function scores (electromyography [EMG], Basso-Beattie-Bresnahan (BBB) test, and narrow beam-walking test [NBT]). These changes were most pronounced in the Hyd + Micro group. The treatment also led to a significant decrease in the counts of apoptotic and glial cells, alongside reduced levels of malondialdehyde (MDA) and pro-inflammatory cytokines (IL-1β and TNF-α), with the most notable enhancements seen in the Hyd + Micro group. These findings indicate that the co-delivery of bFGF and IL-10 encapsulated in microspheres within a collagen-based hydrogel provides enhanced neuroprotective effects in TSCI animal models.

2025-10-01·JOURNAL OF VASCULAR SURGERY

Opioid use patterns and persistent use after hemodialysis access surgery

Article

作者: Wisk, Lauren E ; Nahm, William J ; Woo, Karen ; Dworsky, Jill Q ; Ku, Elaine ; Copeland, Timothy P ; Martin, Emily J

OBJECTIVE:

We evaluated the risk of persistent opioid use related to opioid pain management for hemodialysis access creation and identify patterns of opioid dosage and use.

METHODS:

This retrospective cohort study included Medicare-enrolled opioid-naïve patients in the US Renal Data System who initiated hemodialysis for end-stage kidney disease between April 2015 and June 2019. Persistent opioid use was defined as an opioid prescription 90 to 180 days after surgery. The Cox proportional hazards model used censored patients at the time of hospitalization, subsequent hemodialysis access procedures, death, and end of Medicare enrollment. A mixed-effect logistic regression modeled opioid prescription, and a mixed-effect linear regression modeled opioid quantity in 5-mg hydrocodone equivalents.

RESULTS:

A total of 28,404 patients (median age, 72 years; 25th, 75th percentile, 66, 79 years; 15,322 men [53.9%]) underwent index access creation, of whom 14,265 patients filled an opioid prescription at access creation (50.2%), with 3289 opioid prescriptions (23.1%) for ≥42 tablets of 5-mg hydrocodone equivalents (ie, ≥2 weeks prescription). Patients receiving ≥42 tablets of 5-mg hydrocodone equivalents (≥2 weeks) had 1.28 times the risk of persistent opioid use (95% confidence interval, 1.08-1.52) relative to those who did not fill an opioid prescription. In contrast, receipt of 20 or fewer tablets of 5-mg hydrocodone equivalents was not associated with an increased risk of persistent opioid use (hazard ratio 1.00; 95% confidence interval, 0.85-1.18).

CONCLUSIONS:

Given the risk of persistent opioid use stemming from hemodialysis access procedures, the development of formal recommendations for conservative hemodialysis access pain management may be worth considering.

2025-09-01·Animal Nutrition

Effects of 25-hydroxyvitamin D3, chondroitin sulfate and glucosamine sulfate on the growth performance, calcium and phosphorus metabolism, and bone development of weaned piglets

Article

作者: Li, Wenxue ; Guo, Xutong ; Tang, Qingsong ; Tang, Zhiru ; Sun, Zhihong ; Xu, Yetong ; Shi, Baoshi ; Xi, Yuyue ; Peng, Xie

This study aimed to determine the effects of 25-hydroxyvitamin D₃ (25-OH-VD₃), combined with chondroitin sulfate (CS) and glucosamine sulfate (GS), on calcium and phosphorus metabolism and bone development of weaned piglets. One hundred weaned piglets (28 d old; Duroc × Landrace × Large White; initial body weight, 7.8 ± 0.22 kg) were randomly assigned to 5 dietary treatments, which included basal diet + 50 μg/kg vitamin D₃ (CON), basal diet + 50 μg/kg 25-OH-VD₃ (HyD), basal diet + 50 μg/kg 25-OH-VD₃ + 800 mg/kg CS (CS), basal diet + 50 μg/kg 25-OH-VD₃ + 1200 mg/kg GS (GS), and basal diet + 50 μg/kg 25-OH-VD₃ + 800 mg/kg CS + 1200 mg/kg GS (CS + GS). The experiment lasted 31 d, including 3 d of acclimation. The results showed that pigs in the HyD and GS groups had a higher (P = 0.006) apparent digestibility of calcium than pigs in the CON group. The bone mineral density and calcium content in the metatarsal and phalangeal bones of piglets in the CS and GS groups were significantly higher (P < 0.05) than those in the CON and HyD groups. The mRNA expression of transient receptor potential cation channel subfamily V member 6 and calcium-binding protein D9K in the colon mucosa and transient receptor potential cation channel subfamily V member 5, solute carrier family 34 member 1, calcium-sensing receptor, and calcium-binding protein D28K in the kidneys of piglets was upregulated (P < 0.05) in the GS group compared to that in the CON, HyD, CS, and CS + GS groups. The protein expression of cytochrome P450 27B1 and calcium-sensing receptor in the kidneys of piglets was upregulated (P < 0.05) in the GS group compared to that in the CON, HyD, and CS + GS groups. Overall, dietary supplementation with 25-OH-VD₃ alone or in combination with GS enhanced bone development in piglets by improving calcium and phosphorus metabolism.

66

项与重酒石酸氢可酮相关的新闻（医药）

2025-08-28

·PRNewswire

Imbed Biosciences Launches Dual-Action Wound Matrix Integrating Bioburden Management and Pain Relief in a Single Solution

MIDDLETON, Wis., Aug. 28, 2025 /PRNewswire/ -- Imbed Biosciences Inc., a leader in advanced wound care technology, today announced the launch of SAM™ PainGuard™ with Lidocaine, a groundbreaking addition to its acute care portfolio of fully synthetic, antimicrobial, and biocompatible wound matrices. This innovation introduces two new product brands: Surgaflex™ PainGuard™, designed for surgical wounds, and Pelashield™ PainGuard™, tailored for burn and trauma wound management. This launch highlights the versatility of Imbed's SAM™ Antimicrobial Technology platform, which uniquely integrates multiple wound care agents into a single matrix composed of bioresorbable polymers. The result is a dual-action solution that delivers both antimicrobial protection and acute pain relief—streamlining wound care and improving patient outcomes. "Nearly 90% of patients report moderate to severe pain following surgery," said Terry Bromley, CEO of Imbed Biosciences. "Managing this pain effectively from the start is critical—not only to reduce reliance on systemic pain medications, including opioids, but also to prevent long-term complications such as anxiety, PTSD, and delayed healing, which can be a challenge especially in burn care." "These clinical challenges were the driving force behind the development of SAM™ PainGuard™," added Gaurav Pranami, Ph.D., Vice President, Research & Development at Imbed. "By incorporating lidocaine alongside antimicrobial silver, we've created a matrix that addresses both bioburden and pain in a convenient, unit-dose format." The PainGuard™ matrix delivers a controlled release of lidocaine HCl comparable to a 4% ointment, with over 80% released within the first 30 minutes to provide immediate pain relief. It is indicated for a wide range of wound types—including surgical, burn, donor site, trauma, and chronic wounds—and is especially beneficial following painful excisions and also procedures such as dressing changes and debridement. Pre-launch product evaluations have resulted in strong endorsements from participating physicians, with testimonials such as the following praising its ability to effectively manage patient pain and offer a convenient solution for clinicians. "This patient stopped taking her hydrocodone on day one, and rates her pain 1/10 since the procedure. This doesn't happen with this type of bunion surgery!" Damian Dauphinee, DPM, Podiatry "The matrix is easy to use, easy to place, and my patient is pain free." Dr. Aaron Cernero, DO, General Surgery Product Highlights Dual-action, ultra-thin matrix combines antimicrobial silver and lidocaine HCl Porous, bioresorbable polymer conforms to wound micro-textures and does not require removal Synthetic composition eliminates product-related infection risks associated with animal-derived products Low, non-toxic levels of ionic and metallic silver provide 72 hours of sustained, 99.99% microbial reduction Acute pain relief for up to 3 hours FDA 510(k)-cleared (K211943) Ready-to-use, unit-dose format for consistent and safe application "We have successfully engineered and translated our unique multi-agent matrix into a clinically-relevant solution that enables uniform coverage and controlled dosing," explains Sanjay Gupta, Vice President, Supply Chain, "with a design that simplifies clinical workflows and reduces possible side-effects by preventing uneven lidocaine applications, which can occur with gels or ointments." Surgaflex™ PainGuard™ and Pelashield™ PainGuard™ are now available in the U.S. and join Imbed's expanding portfolio of SAM™-based wound care solutions, which includes Microlyte®, Surgaflex™, and Pelashield™, indicated for chronic, acute, and burn wounds respectively. About Imbed Biosciences Inc. Imbed Biosciences is a privately held medical device company pioneering the next generation of wound care with SAM™ Antimicrobial Technology. SAM™ acts as a platform, designed to integrate multiple therapeutic agents into ultra-thin, biocompatible matrices to support skin regeneration and healing while managing bioburden, across a wide range of acute and chronic wounds. For more information, visit ImbedBio.com and connect with us on LinkedIn, Instagram, and Facebook. Media Contact: Hillary Rush Vice President of Marketing Imbed Biosciences Inc. 📧 [email protected] 🌐 SOURCE Imbed Biosciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-08-05

·新药猎人笔记

Vertex盘前大跌：Nav1.8抑制剂遭双杀

2025年8月5日，Vertex Pharmaceuticals公司宣布，其在研的非阿片类止痛药VX-993在治疗拇囊炎切除术后急性疼痛的二期临床试验中未能达到主要终点。受此消息影响，Vertex公司股价盘前大跌13%！该试验是一项双盲、安慰剂对照研究，共招募了367名接受拇囊炎切除手术的患者。试验测试了三种口服剂量的VX-993（180/90毫克、70/35毫克和10/5毫克），并评估了它们与安慰剂相比减轻术后急性疼痛的能力。试验结果在一项涉及 367 人的研究中，术后48小时内，该药物的三种剂量均未显著优于安慰剂。尽管较高剂量在数值上表现较好，但其效果仍逊于服用常见止痛药氢可酮/对乙酰氨基酚（商品名：维柯丁）的患者组。最常见的不良事件包括恶心、头晕、头痛和呕吐。这表明VX-993在安全性方面表现良好，但其疗效仍需进一步优化。基于这些结果，公司不再将VX-993作为急性疼痛的单一疗法进行研究。该公司还在进行VX-993用于糖尿病周围神经病变（一种慢性疼痛）的二期临床试验，计划招募约300名患者。图源：https://www.biopharmadive.com/news/vertex-pain-non-opioid-drug-fda-approval-journavx/738721/ 此外，不再计划对已获批的Nav1.8抑制剂 Journavx 进行治疗坐骨神经痛的三期临床试验。这一决定是在美国食品药品监督管理局告知该公司“他们看不到”获得外周神经性疼痛（包括糖尿病周围神经病变等慢性疼痛）广泛适应症的途径之后做出的。结束语： VX-993是Vertex公司开发的下一代Nav1.8钠通道抑制剂，旨在通过选择性抑制Nav1.8通道来阻断外周神经系统中的疼痛信号传递。此前，Vertex的另一款Nav1.8抑制剂VX-548已获得美国FDA批准用于治疗中度至重度急性疼痛，并显示出良好的疗效和安全性。一日两款Nav1.8抑制剂遭双杀，Vertex想要突破更多的疼痛适应症还有漫长的路要走。

临床2期临床3期

2025-08-05

·药时代

打不过安慰剂？如何冲击千亿美元市场

全文共2000字，共1图预计阅读时间：5分钟在非阿片类镇痛药的研发中，Vertex遭遇了新的挫折。其Nav1.8钠通道抑制剂VX-993在一项2期临床试验中未能在疼痛缓解方面优于安慰剂效果。该结果于8月4日美股收盘后公布。与此同时，Vertex透露，美国FDA将拒绝批准Journavx（VX-548）用于更广泛的适应症。这一系列不利消息，让刚公布第二季总收入29.6亿美元，同比增长12%的Vertex根本笑不起来。逊于安慰剂这项双盲、安慰剂对照研究共纳入367名接受拇囊炎（拇外翻）手术的患者。试验测试了VX-993的三种口服剂量，并评估其在术后急性疼痛中的镇痛效果。研究的主要终点指标为SPID48（0至48小时疼痛强度差值的时间加权总和），该指标综合反映疼痛缓解的程度与持续时间。SPID48值越高，表明48小时内累积的镇痛效果越好。来源：Vertex官方披露虽然猛一看， VX-993各剂量试验组的SPID48数值均略高于安慰剂组，但P值远大于医学研究中设定的0.05，这就有理由怀疑这个差异是因为运气，而非药物的真实效果。此外，三个剂量组的置信区间均包含0（即无差异）甚至负值（表示可能劣于安慰剂），进一步表明其疗效缺乏统计学支持。值得注意的是，作为阳性对照的活性药物组（氢可酮/对乙酰氨基酚）表现出显著优于安慰剂的镇痛效果（SPID48差异为44.2，95% CI: 14.0–74.4，p=0.0043 < 0.05）。这一阳性结果具有重要意义，它验证了：研究设计的科学性，具备检测有效镇痛作用的能力；患者人群的代表性，对已知有效药物有预期反应；疼痛评估方法的敏感性，能够准确捕捉疼痛变化；安慰剂效应是在预期范围内的。这些试验数据再次强有力地支持了结论：VX-993在三种剂量下，均未在术后48小时内显著缓解疼痛，其效果甚至可能略逊于安慰剂。这并非源于试验设计或执行缺陷，而是该药物本身疗效不足。欣慰的是，VX-993的安全性数据与安慰剂相似，最常见的不良反应包括恶心、头晕、头痛和呕吐。珠玉在前，为何还推出VX-993 作为NaV1.8领域的领头羊，Vertex先后折戟VX-128，VX-961，VX-150等多个分子，或因剂量安全性问题，或因PK特征不符合开发要求。重磅止痛药Journavx成功地提高了NaV1.8抑制活性和选择性，但似乎在糖尿病周围神经痛（DPNP）和疼痛性腰骶神经根病（LSR）上的疗效依然比较有限。在2期的临床中发现，Journavx Day1的平均Tmax为6h,但活性代谢产物血药浓度达峰时间(Tmax)间为12h。对于急性疼痛，如果可以进一步缩短达到Tmax 的时间，尤其是活性药物Tmax 的进一步缩短，可以显著提高药物起效时间。这或许也是Vertex快速推进VX-993临床开发的原因，希望通过结构优化，在药效和药代动力学（PK）等方面实现进一步提升，以开发出安全性、有效性优于Journavx的新一代非阿片类镇痛疗法。然而，“升级版”第三代的VX-993还是未能超越Journavx的出色疗效【3期临床数据显示，在接受拇囊炎切除手术的患者中，Journavx疗法的SPID48平均差异为29.3（95% CI：14.0，44.6；P=0.0002）】，甚至在关键研究中未能显示出优于安慰剂的效果，铩羽而归。 FDA拒批“魔掌”伸向Vertex 不过，Journavx近日也摊上事了。Vertex公司透露，美国FDA目前不愿批准其用于广泛治疗周围神经性疼痛。今年1月底，Journavx已获FDA批准上市，成为近25年来首个获批的新型止痛药，也是自20世纪80年代以来首款非阿片类急性疼痛治疗药物。这一突破曾被寄予厚望，有望为美国止痛药市场带来颠覆性变革，助力缓解日益严峻的阿片类药物滥用危机。然而，美中不足的是，该药目前仅被批准用于治疗中至重度急性疼痛，其适用范围仍较为有限，大量慢性疼痛等临床需求尚未覆盖。此次FDA拒绝扩展其适应症，尽管令人遗憾，但在当前FDA高层人事变动的背景下，对监管审批呈审慎态度也不意外。药时代近期在《多款药物惨遭FDA拒批！居然因为... 》中报道过：细胞疗法Deramiocel和溶瘤病毒疗法RP1等多个项目均因人事变动收到了CRL。鸦片危机催生千亿金矿 VX-993的临床开发失败，叠加Journavx扩展适应症被拒，令资本市场对Vertex公司的前景产生复杂情绪。然而，业内人士普遍认为，此次风波的“余震”不会持续太久，对Journavx等Nav1.8钠通道抑制剂的整体市场潜力仍持乐观态度。无上瘾性的止痛药是美国急需的，而这恰恰是Journavx最大的卖点。 Journavx精准靶向Nav1.8钠通道，这一通道特异性表达于外周疼痛感知神经元中。这一机制优势意味着药物可有效阻断疼痛信号的传递，而不会干扰心脏或中枢神经系统功能。由于作用机制是阻断这条外周通路，因此不会像阿片类药物那样激活大脑奖赏系统、引发欣快感或成瘾风险，从根本上规避了滥用隐患。这一特性在当前美国深陷“阿片危机”的背景下显得尤为可贵。自1999年以来，美国已有超过19万人死于奥施康定等阿片类止痛药物的滥用。根据美国缉毒局（DEA）数据，2023年全美因药物过量致死人数超过10.7万，其中近70%由芬太尼及其他阿片类物质引发。美国国会联合经济委员会2022年发布的报告指出，阿片类药物滥用已给美国经济造成近1.5万亿美元的损失，约占当年GDP的7%。严峻的公共卫生危机催生了一个巨大的“蓝海”市场。据Mordor Intelligence数据显示，2021年全球疼痛管理市场规模达794亿美元，预计到2027年将攀升至1207亿美元，年复合增长率达7.39%。在GLP-1类减肥药热潮之后，镇痛药被视为下一个有望突破千亿级美元的医药“金矿”。若Vertex能凭借Journavx率先确立在无成瘾性止痛药领域的领导地位，其市场前景不可估量。但其它管线若想和Journavx打擂台，还是先打过安慰剂吧！，参考资料： 1.https://www.fiercebiotech.com/biotech/vertex-drops-journavx-follower-acute-pain-after-complete-phase-2-failure 2.安慰剂疗效显著？Vertex一夜蒸发130亿美元（药时代） 3.止痛药 “觉醒时代” 开启（药时代）4.https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-results-phase-2-study-vx-993-treatment-acute 5.Na1.8- VX-548依然有巨大改进的空间（Healthcare Weekly) 6.值Vertex一季报之际，一窥其疼痛管理管线(MNC观察) 7.营收逆势增长12%，却被FDA和管线双重泼冷水，Vertex遭遇“甜苦交加”一日(思索新知) 8.其他公开资料图片来源：即梦AI 2025-08-05 Q2亏损8亿美元、裁员10%、CEO拒绝并购交易 2025-08-04 患者死亡！通用型CAR-T先驱遇挫 2025-08-04 版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击这里，查看更多精彩！

100 项与重酒石酸氢可酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	重酒石酸氢可酮	R05DA03	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
疼痛	美国	Societal CDMO Gainesville LLC	2013-10-25

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨关节炎	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2010-11-01
慢性疼痛	临床3期	美国	Zogenix, Inc.	2010-05-01
腰痛	临床3期	美国	Zogenix, Inc.	2010-03-01
慢性骨关节炎	临床2期	-	Zogenix, Inc.	2002-09-01
术后疼痛	临床2期	-	Zogenix, Inc.	2002-08-01
终末期肾脏病	临床1期	美国	Cephalon, Inc.	2011-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01402375 (CTgov)	临床3期	镇痛 \| 急性疼痛	720	Hydrocodone (first trial) (Hydrocodone (First Trial))	選夢願齋壓鑰齋網壓蓋(網齋製構壓廠觸憲鹹夢) = 淵願鑰築醖醖淵顧衊選糧顧遞餘蓋壓製簾選製 (製淵遞糧淵襯願鏇艱築, 1.7) 更多	-	2018-05-01
				Codeine (Codeine (First Trial))	選夢願齋壓鑰齋網壓蓋(網齋製構壓廠觸憲鹹夢) = 築鹹簾齋觸顧鹽壓鹽積糧顧遞餘蓋壓製簾選製 (製淵遞糧淵襯願鏇艱築, 1.8) 更多
NCT01240863 (CTgov)	临床3期	腰痛 \| 骨关节炎 \| 慢性疼痛	391	Placebo (Placebo (Double-blind Treatment Period))	鬱糧選鬱夢構觸醖遞鹽(淵壓窪鑰鏇淵顧鬱糧遞) = 齋艱壓襯願繭網鹹衊窪顧夢獵觸顧願壓鹹築鏇 (繭糧鑰壓艱繭廠繭鬱鏇, 0.169) 更多	-	2017-06-05
				Hydrocodone ER (Hydrocodone ER (Double-blind Treatment Period))	鬱糧選鬱夢構觸醖遞鹽(淵壓窪鑰鏇淵顧鬱糧遞) = 願糧獵選鏇糧衊艱製齋顧夢獵觸顧願壓鹹築鏇 (繭糧鑰壓艱繭廠繭鬱鏇, 0.176) 更多
NCT01922739 (CTgov)	临床3期	腰痛	182	Placebo+Hydrocodone ER	獵糧艱鬱衊繭顧網鏇鏇 = 顧製壓鹽選餘夢簾願餘淵艱觸製艱蓋構願齋鏇 (鹽鬱繭網願淵築壓齋鹹, 構選餘艱醖遞窪衊窪廠 ~ 範遞網願膚鏇鏇築簾鑰) 更多	-	2017-06-02
NCT01789970 (CTgov)	临床3期	腰痛	625	Placebo (Placebo (Double-blind Treatment Period))	繭遞遞鏇糧顧製鏇觸築(醖齋窪糧壓廠廠襯廠鏇) = 淵夢鏇遞選願淵鹽齋夢夢夢製窪窪遞積壓構衊 (願獵餘網構網衊網網艱, 0.145) 更多	-	2017-04-05
				Hydrocodone ER (Hydrocodone ER (Double-blind Treatment Period))	繭遞遞鏇糧顧製鏇觸築(醖齋窪糧壓廠廠襯廠鏇) = 膚廠醖廠積鹹選鑰簾觸夢夢製窪窪遞積壓構衊 (願獵餘網構網衊網網艱, 0.134) 更多
NCT01517295 (CTgov)	临床4期	慢性疼痛	30	Hydrocodone (Group 1)	蓋鏇衊積獵積夢膚鬱積(簾鏇齋構壓窪鏇遞積簾) = 鹹衊憲積範觸鹹憲衊範壓範鑰衊鹹蓋蓋夢遞構 (鹹襯簾遞網積簾艱積憲, 0) 更多	-	2016-07-28
				Hydrocodone (Group 2)	蓋鏇衊積獵積夢膚鬱積(簾鏇齋構壓窪鏇遞積簾) = 範艱壓膚壓膚鬱窪襯齋壓範鑰衊鹹蓋蓋夢遞構 (鹹襯簾遞網積簾艱積憲, 0) 更多
NCT01859715 (CTgov)	N/A	药物相互作用	502	Oxycodone (Oxycodone Group)	積繭鏇築艱夢鏇憲醖蓋(鬱製襯醖淵艱遞窪壓鬱) = 顧積淵簾製鏇襯鹹範膚繭餘壓膚窪積範鏇繭艱 (積鏇願鏇淵積蓋壓憲繭, 網顧壓襯選鑰蓋醖衊遞 ~ 鹹構願範範觸餘夢範鹹) 更多	-	2016-05-05
				Hydrocodone (Hydrocodone/Acetaminophen Group)	積繭鏇築艱夢鏇憲醖蓋(鬱製襯醖淵艱遞窪壓鬱) = 選醖衊廠鹹淵齋鹹艱遞繭餘壓膚窪積範鏇繭艱 (積鏇願鏇淵積蓋壓憲繭, 鹹窪艱簾廠鬱鏇遞壓遞 ~ 淵鏇構繭鬱築鬱壓蓋獵) 更多
NCT01400139 (CTgov)	临床3期	慢性疼痛	922	Hydrocodone bitartrate (HYD) (HYD Core Study)	衊夢顧餘築範觸鑰範鬱 = 艱鹽製鹹壓鬱鹽製鏇製壓獵憲願襯襯願膚觸製 (壓壓衊鬱窪窪鑰餘築遞, 夢鑰淵選膚襯餘簾壓築 ~ 製顧願淵製憲窪範積壓) 更多	-	2014-12-04
				Hydrocodone bitartrate (HYD) (HYD Extension Period)	衊夢顧餘築範觸鑰範鬱 = 艱鑰積構衊鏇廠襯夢鬱壓獵憲願襯襯願膚觸製 (壓壓衊鬱窪窪鑰餘築遞, 遞網範鹹遞築網憲淵顧 ~ 膚遞餘鬱觸構製繭積壓) 更多
NCT01452529 (CTgov)	临床3期	腰痛	905	Hydrocodone bitartrate (Hydrocodone Bitartrate)	膚艱鏇廠蓋壓簾鏇艱顧(艱糧鏇廠壓製膚範餘遞) = 築積鹹夢遞鹹遞鹽範窪糧繭願遞淵糧齋願選膚 (鏇艱齋膚範鏇膚糧衊淵, 0.13) 更多	-	2014-12-04
				Placebo to match hydrocodone bitartrate q24h tablets (Placebo)	膚艱鏇廠蓋壓簾鏇艱顧(艱糧鏇廠壓製膚範餘遞) = 鬱願窪簾淵憲網鏇鏇觸糧繭願遞淵糧齋願選膚 (鏇艱齋膚範鏇膚糧衊淵, 0.13) 更多
NCT01115569 (CTgov)	临床3期	慢性疼痛	424	Hydrocodone Bitartrate (Open-label Hydrocodone Bitartrate Extended Release Capsules)	範蓋蓋製觸鏇鏇蓋憲鹹(襯窪壓製鏇廠繭糧齋製) = 糧衊廠糧壓鏇齋鏇艱構製選築窪夢願糧鏇願顧 (壓餘簾糧選選積鹹膚淵, 2.2)	-	2014-04-25
				Hydrocodone Bitartrate (Conversion/Titration Phase)	襯淵鑰鏇淵廠鏇窪衊顧(窪顧鹹鏇齋鹽衊醖選膚) = 遞範醖窪艱遞艱醖夢選製壓遞遞淵廠艱壓蓋衊 (齋鑰選顧壓鬱窪蓋鏇顧, 鑰構衊窪醖齋顧窪襯遞 ~ 積鏇窪築積齋夢鏇鹽餘) 更多
NCT01081912 (CTgov)	临床3期	腰痛	510	Hydrocodone bitartrate (Hydrocodone Bitartrate Capsules)	壓鬱齋鹹網蓋鏇醖鑰膚(餘艱齋願淵齋鹽網衊鏇) = 觸憲觸膚醖獵獵鏇顧築範夢齋獵製網觸網鏇齋 (淵窪餘積鏇齋製構憲選, 1.563)	-	2014-04-21
				Placebo (Placebo Comparator)	壓鬱齋鹹網蓋鏇醖鑰膚(餘艱齋願淵齋鹽網衊鏇) = 構鬱艱積衊艱製鏇餘簾範夢齋獵製網觸網鏇齋 (淵窪餘積鏇齋製構憲選, 1.550)